Europäische Union - Schwedisch - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektiva immunsuppressiva medel - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

alliance pharma (ireland) ltd - terlipressinacetat - injektionsvätska, lösning - 0,2 mg/ml - terlipressinacetat 0,2 mg aktiv substans - terlipressin

Europäische Union - Schwedisch - EMA (European Medicines Agency)

the medicines company uk ltd - bivalirudin - akut koronarsyndrom - antitrombotiska medel - angiox är indicerat som en antikoagulans hos vuxna patienter som genomgår perkutan koronar intervention (pci), inklusive patienter med st-segment-höjningsinfarkt (stemi) som genomgår primär pci. angiox är också indicerat för behandling av vuxna patienter med instabil angina / icke st-segment-höjningsinfarkt (ua / nstemi) planeras för brådskande eller tidig intervention. angiox bör ges tillsammans med acetylsalicylsyra och klopidogrel.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

grünenthal gmbh - lesinurad - hyperurikemi - antigout preparat - zurampic, är i kombination med en xantin oxidas hämmare, indicerat till vuxna för adjuvant behandling av hyperurikemi i gikt patienter (med eller utan tophi) som inte har uppnått målet serum urinsyranivåer med en lämplig dos av ett xantin-oxidas hämmare ensam.

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

glaxosmithkline ab - cefuroximnatrium - pulver till infusionsvätska, lösning - 1,5 g - cefuroximnatrium 1,052 mg aktiv substans - cefuroxim

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan hospital as - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 1,5 g - cefuroximnatrium 1,5 g aktiv substans - cefuroxim

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

stragen nordic a/s - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 1,5 g - cefuroximnatrium 1,578 g aktiv substans - cefuroxim

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

glaxosmithkline ab - cefuroximnatrium - pulver till infusionsvätska, lösning - 1,5 g - cefuroximnatrium 1,58 g aktiv substans - cefuroxim

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

sandoz a/s - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 1,5 g - cefuroximnatrium 1,58 g aktiv substans - cefuroxim

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

navamedic asa - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 1500 mg - cefuroximnatrium 1578 mg aktiv substans - cefuroxim